| Content Provider |
World Health Organization (WHO)-Global Index Medicus |
| Author |
Carvalho, Pamela Castilho Santos, Edson Anjos Schneider, Beatriz Ursinos Catelán Matuo, Renata Pesarini, João Renato Cunha-Laura, Andréa Luiza Monreal, Antônio Carlos Duenhas Lima, Dênis Pires Antoniolli, Andréia Conceição Milan Brochado Oliveira, Rodrigo Juliano |
| Description |
Author Affiliation: Carvalho PC ( Center for Stem Cells, Cell Therapy and Genetic Toxicology Studies (Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen), Maria Aparecida Pedrossian University Hospital (Hospital Universitário Maria Aparecida Pedrossian), EBSERH (Empresa Brasileira de Serviços Hos); Santos EA ( Biochemistry Laboratory, Center for Biological and Health Sciences, Federal University of Mato Grosso do Sul (Universidade Federal do Mato Grosso do Sul - UFMS), Campo Grande, Mato Grosso do Sul, Brazil.); Schneider BU ( Center for Stem Cells, Cell Therapy and Genetic Toxicology Studies (Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen), Maria Aparecida Pedrossian University Hospital (Hospital Universitário Maria Aparecida Pedrossian), EBSERH (Empresa Brasileira de Serviços Hos); Matuo R ( Center for Stem Cells, Cell Therapy and Genetic Toxicology Studies (Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen), Maria Aparecida Pedrossian University Hospital (Hospital Universitário Maria Aparecida Pedrossian), EBSERH (Empresa Brasileira de Serviços Hos); Pesarini JR ( Center for Stem Cells, Cell Therapy and Genetic Toxicology Studies (Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen), Maria Aparecida Pedrossian University Hospital (Hospital Universitário Maria Aparecida Pedrossian), EBSERH (Empresa Brasileira de Serviços Hos); Cunha-Laura AL ( Master's Program in Pharmacy, Center for Biological and Health Sciences (Centro de Ciências Biológicas e da Saúde - CCBS), UFMS, Campo Grande, Mato Grosso do Sul, Brazil.); Monreal AC ( Master's Program in Pharmacy, Center for Biological and Health Sciences (Centro de Ciências Biológicas e da Saúde - CCBS), UFMS, Campo Grande, Mato Grosso do Sul, Brazil.); Lima DP ( Graduate Program in Chemistry, Institute of Chemistry (Instituto de Química - IQ), UFMS, Campo Grande, Mato Grosso do Sul, Brazil.); Antoniolli AC ( Center for Stem Cells, Cell Therapy and Genetic Toxicology Studies (Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen), Maria Aparecida Pedrossian University Hospital (Hospital Universitário Maria Aparecida Pedrossian), EBSERH (Empresa Brasileira de Serviços Hos); Oliveira RJ ( Center for Stem Cells, Cell Therapy and Genetic Toxicology Studies (Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen), Maria Aparecida Pedrossian University Hospital (Hospital Universitário Maria Aparecida Pedrossian), EBSERH (Empresa Brasileira de Serviços Hos) |
| Abstract |
Combretastatin A-4 exhibits efficient anti-cancer potential in human tumors, including multidrug-resistant tumors. We evaluated the mutagenic, apoptotic and immunomodulatory potential of two diaryl sulfide analogs of combretastatin A-4, 1,2,3-trimethoxy-5-([4-methoxy-3-nitrophenyl]thio)benzene (analog 1) and 1,2,3-trimethoxy-5-([3-amino-4-methoxyphenyl]thio)benzene (analog 2), as well as their association with the anti-tumor agent cyclophosphamide, in Swiss mice. Such evaluation was achieved using the comet assay, peripheral blood micronucleus test, splenic phagocytosis assay, and apoptosis assay. Both analogs were found to be genotoxic, mutagenic and to induce apoptosis. They also increased splenic phagocytosis, although this increase was more pronounced for analog 2. When combined with cyclophosphamide, analog 1 enhanced the mutagenic and apoptotic effects of this anti-tumor agent. In contrast, analog 2 did not enhance the effects of cyclophosphamide and prevented apoptosis at lower doses. These data suggest that analog 1 could be an adjuvant chemotherapeutic agent and possibly improve the anti-neoplastic effect of cyclophosphamide. Additionally, this compound could be a candidate chemotherapeutic agent and/or an adjuvant for use in combined anti-cancer therapy. |
| File Format |
HTM / HTML |
| ISSN |
13826689 |
| Issue Number |
3 |
| Volume Number |
40 |
| e-ISSN |
18727077 |
| Journal |
Environmental Toxicology and Pharmacology |
| Language |
English |
| Publisher |
Elsevier |
| Publisher Date |
2015-11-01 |
| Publisher Place |
Netherlands |
| Access Restriction |
One Nation One Subscription (ONOS) |
| Subject Keyword |
Discipline Environmental Health Discipline Pharmacology Antineoplastic Agents, Phytogenic Administration & Dosage Dna Drug Effects Sulfides Animals Pharmacology Apoptosis Cell Survival Cyclophosphamide Drug Synergism Humans Male Mice Micronucleus Tests Phagocytosis Stilbenes Chemistry Journal Article Research Support, Non-u.s. Gov't |
| Content Type |
Text |
| Resource Type |
Article |
| Subject |
Health, Toxicology and Mutagenesis Medicine Toxicology Pharmacology |
